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ABSTRACT
   S. aureus is a rising health issue due to it's high pathogenicity, mortality and drug resistance. Due 
to the failed antibiotic treatment of multidrug resistant S. aureus like MRSA it is important to look 
for alternative therapies. Human innate immunity might be one such therapy. It will be shown here
that an innate immunity induction via either MyD88-dependent PRRs or via an HIF-1 activation 
could be the answer, was it not for S. aureus ability to destroy neutrophiles and macrophages. This 
makes the innate immunity activation therapy a game of chance, should this therapy used alone. 
The innate immunity therapy might be promising though when used together with vaccination. 
And an IL-1 receptor, the activator of B cells, might be just an example of that.
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INTRODUCTION
    According to the European Antimicrobial Resistance Surveillance System (EARSS) Annual Report 
2008, funded by the European Center for Disease Prevention and Control (ECDC), there were 
reported 31.819 invasive Staphylococcuas aureus (S. aureus) isolates from 33 European countries 
21% of which were Methicillin-resistant Staphylococcus aureus (MRSA) strains  [ECDC 2008]. In 2013 
The Center for Disease Control and Prevention (CDC) described Staphylococcus as the leading 
cause of healthcare-associated infections and gave an annual estimate of 80.461 of severe MRSA 
infections and 11.285 death incidents related to them in the United States of America alone. CDC 
also described Vancomycin-resistant Staphylococcus aureus (VRSA) as one of the microorganisms 
with the threat level of concerning do to few available therapeutic options [CDC 2013]. In 2014 
Denmark registered 2.965 individuals infected with MRSA – this was so far the highest number of 
it's citizens, infected with this bacteria [Bager et al. 2014].
   All this shows the importance of timely and correctly addressing this deadly threat posed by S. 
aureus.
MOTIVATION & AIMS
   The aim of this text is to find out whether the innate immunity induction could be used as a 
therapy against S. aureus infection.
FOCUS AREA
   The focus area of this text is to look at S. aureus, it's pathogenicity and multidrug resistance and 
to find out whether an innate immunity activation by an immunogen can be used as a therapy 
against S. aureus infection. The scope of this text would be around a short relevant insight of S. 
aureus characteristics, virulence, related diseases, the human immunity and use of it's innate 
branch as a therapeutic approach.
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1. STAPHYLOCOCCUS AUREUS
1.1 STAPHYLOCOCCUS AUREUS, BACKGROUND
   Staphylococcus aureus is a member of the Micrococcaceae family [Lowy 1998]. S. aureus bacteria is
a gram-positive coccus which in it's commensal form is present on 30-50 percent of all humans 
[Madigan et al. 2003; Sundhedsstyrelsen 2012; Bager et al. 2014]. It's colonization sites on humans are 
primarily nares and skin. There are different genetic variations of S. aurus worth mentioning. Those
are methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus 
aureus (MRSA), Glycopeptide-intermediate Staphylococcus aureus (GISA) or Vancomycin-
intermediate Staphylococcus aureus (VISA) [Appelbaum 2006; Zhanel et al 2009].
   S. aureus was discovered by a Scottish surgeon Alexander Ogston in 1880 . He called them 
Staphylococcus (Greek for “bunch of grapes”) after he observed those cocci living in grape-like 
clusters. Rosenbach was the first to isolate this bacteria and call it aureus (Latin for “gold”) because
of the yellow-orange color of the colonies [van Belkum et al. 2009].
1.2 STAPHYLOCOCCUS AUREUS, HUMAN DISEASES
   Among over 30 Staphylococcus species known aureus is the most pathogenic one [van Belkum et al.
2009].
   The most prevalent form of disease caused by S. aureus is skin and soft-tissue infections (SSTI). 
SSTI can further develop into bacteremia and invasive disease like sepsis, bloodstream infection 
and infective endocarditis. S. aureus can also cause osteomyelitis, pneumonia, infectious arthritis, 
abscesses in many tissues and infections of surgical wounds [van Belkum et al. 2009; David & Daum 2010; 
Thammavongsa et al. 2015]. MRSA can further be linked to necrotizing pneumonia, necrotizing fasciitis,
severe sepsis and some cases of septic thrombophlebitis of large veins [David & Daum 2010]. The life 
threatening forms of disease associated with S. aureus will discussed below. Those are bacteremia,
endocarditis, sepsis, metastatic infections and toxic shock syndrome.
Bacteremia
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   The mortality rate associated with staphylococcal bacteremia was about 11 - 43 % during 
nienties. Factors which increased the mortality were the age over 50 and some the presence of 
some other form of disease. The frequency of complication from this type of bacteremia was 11 - 
53 %. About 31 % of those who didn't develop endocarditis on basis of bacteremia had metastatic 
infection. Many cases of bacteremia were related to catherization [Lowy 1998].
Endocarditis
   S. aureus was involved in 25 - 35 % of all infective endocarditis (IE) cases up until nienties [Lowy 
1998]. In the beginning of the new millennium IE still was addressed to a high rate of S. aureus 
infection. Up until 2009 the mortality rate associated with IE was 15 - 20 % [Murdoch et al. 2009].    IE 
is primarily occurring among intravenous drug users, prosthetic valve users, elderly people and 
hospitalized patients in general. S. aureus mediated endocarditis is characterized by a rapid 
development of the disease, high fever, frequent involvement of cardiac valves and absence of the 
symptoms at the initial stage. It is rather difficult to diagnose IE [Lowy 1998].
   One study showed that in 83 % of 2756 IE cases was caused by a gram-positive bacteria, 31 % of 
those gram-positive occurrences were S. aureus [Murdoch et al. 2009].
   S. aureus is the predominant pathogen associated with the nosocomial form of the disease. The 
mortality rate for the nosocomial version of IE is 40 – 56 %. This number is even higher for IE 
caused by S. aureus [Lowy 1998].
   Today there is a 1 - 5 % incidence of IE cases that are ascribed to intravenous drug users. The 
majority of those patients are young do not have any reported cases of cardiac disease prior to 
that. The tricuspid valve is infected in 50 % of cases [Lowy 1998; Prendergast 2006]. The disease is right-
sided in most cases of drug abuse related IE. The mortality rate is relatively low unless patients are 
bearers of human immunodeficiency virus (HIV) when diagnosed with IE.
   In the case where the intravenous drug use was not the case the disease is left-sided, the 
patients are older, and the mortality rate is about 20 – 44 % for. In this case the disease is often 
associated with previously damaged cardiac valves [Lowy 1998]. Prosthetic valve endocarditis is 
responsible for 10 - 15 % of all cases with an annual occurrence of 0,1 - 2,3 % [Prendergast 2006]. S. 
aureus is again the most common pathogen associated with this type of IE [Lowy 1998].
  The initial bacterial valve conization by S. aureus could be understood as a biological mechanism 
consisting of three stages. During the first stage endothelial cells express integrins that bind plasma
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fibronectin in response to local inflammation. S. aureus binds to fibronectin through it's fibronectin
binding proteins. This results in the endothelial internalization of S. aureus. During the second 
stage the endothelial cells produce cytokines and TfA in response to the invasion by S. aureus. This 
triggers blod clotting and extension of inflammation. During the last stage the internalized S. 
aureus lyses the endothelial cells by excreting hoemolysins [Prendergast 2006].
Nectrotizing Pneumonia
   Necrotizing pneumonia is characterized by leukopenia, hemoptysis and extensive necrosis of the 
lung tissue. The disease is associated with pore-forming Panton-Valentine Leukocidin (PVL) – one 
of the toxins produced by S. aureus [Lina et al. 1999; Labandeira-Rey et al. 2007].
Metastatic Infections
   S. aureus has a tendency to spread to particuar areas of the organism like bones, joints, kidneys 
and lungs. Once invaded by S. aureus those sites could become the sources of the recurrent 
infection by this organism [Lowy 1998]. 
Sepsis
   Only a minority of the bacterial infections end up as sepsis. The main factors associated with it 
are an advanced age, invasive measures, a chemotherapy and an immunosuppresion. S. aureus is 
the most common pathogen associated with sepsis. In severe cases sepsis can evolve into a 
multiorgan disfunction and a disseminated intravascular coagulation [Lowy 1998].
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2. BACKGROUND ON HUMAN IMMUNITY & VIRULENCE OF STAPHYLOCOCCUS
2.1 GENERAL OVERVIEW OF HUMAN IMMUNITY
Immunity
   The goal of this chapter is to make a very brief overview of the human immunity system.
   The human immune system is consisting of two branches: the innate immune system and the 
acquired immune system.
   The innate immune system is the first defensive response against a pathogen infection. This type 
of response is immediate but not very specific, when it comes to recognition of different 
pathogens. Because of this lack of specificity the innate immune system sometimes damages 
normal tissues of the host [Parkin & Cohen 2001; Campbell et al. 2015; Gumbleton & Furr 2004; Widmaier et al. 
2008]. The term antigen refers to a pathogen part which gives rise to a primary interaction with the 
immune system [Gumbleton & Furr 2004]. If the antigen elicits an immune response it is defined as an 
immunogen [Delves & Roitt 2000; Gumbleton & Furr 2004].
Innate Immunity
 The innate immune system can be further divided in to two parts: the barrier defense and the 
internal defense. The barrier defense is when host meets the infection at it's physiological barriers 
like skin or mucous membranes (like nares and similar). The skin is protected by both commensal 
microorganisms and a secreted hydrolytic enzyme like lysozyme (a peptidoglycan hydrolase). Low 
pH of the skin also plays a protective role against infection. The internal defense gets activated 
once the infection pentrates the aforementioned physiological barrier. It is mediated primarily by 
natural killer (NK) cells, eosinophiles and phagocytes. Those phagocytes are neutrophiles, 
macrophages and macrophage-like dendritic cells (DCs). Phagocytes engulf the pathogens during a 
process called phagocytosis [Akira et al. 2006; Parkin & Cohen 2001; Campbell et al. 2015; Gumbleton & Furr 
2004; Widmaier et al. 2008]. When inside the pathogen is subjected to a lytic digestion by highly 
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reactive substances like reactive oxygen species (ROS), internally secreted by the engulfing 
phagocytes. A neutrophile ROS production is also known as an oxidative burst. Those ROS 
substances are a superoxide, a hydrogen peroxide and hydroxyl radicals [Spaan et al. 2013a; Campbell 
et al. 2015; Gumbleton & Furr 2004]. Macrophages do either migrate throughout the human body or 
reside in the specific regions where infections are most likely to occur. Neutrophiles circulate in the
blood. DCs mainly populate skin. Eosinophiles are situated beneath the mucosal surface where 
they can combat parasites (worms and like) by releasing toxins. NK cells do not exert phagocytosis. 
Instead they act cytotoxically against either virus infected or tumor-like cells of the host. NK cells 
are to be found throughout the human body [Akira et al. 2006; Parkin & Cohen 2001; Campbell et al. 2015; 
Gumbleton & Furr 2004; Widmaier et al. 2008]. Neutrophiles and eosinophiles are white blood cells known
as leukocytes [Widmaier et al. 2008]. Neutrophils are at the core of combating S. aureus infections 
[Bogomolski-Yahalom & Matzner 1995; Mölne et  al. 2000; Miller & Cho 2011].
   There is an alternative complement pathway, although it's role in innate immunity is outside the 
scope of this text [Parkin & Cohen 2001; Gumbleton & Furr 2004] It is consisting of about 30 proteins 
[Thammavongsa et al. 2015; Gumbleton & Furr 2004].
   The innate immunity is also characterized by an inflammatory response, during which a lot of 
singnal molcules inovolved with immunity induction Among them are cytokines, chemokines and 
histamines. Cytokines promote blood flow to the area of infection. Histamines make blood vessels 
more dilated and permeable and at the same time atract phagocytes. All this contributes to an 
increased flow of phagocytes to the infected area  [Campbell et al. 2015; Gumbleton & Furr 2004].
Innate Immunity, Pathogen Recognition
   The innate immune system recognizes pathogens by their specific molecular patterns. Those 
patterns are characteristic for the invading microorganisms. Those patterns are essential for the 
microorganisms and therefore are difficult for it to alter in order to combat the innate system of 
the host. They are also known as pathogen-associated molecular patterns (PAMP). 
   Those PAMP regions are recognized by the innate immunity system through it's pattern-
recognition receptors (PRR). The PRR receptors that endothelial cells and phagocytes like 
macrophages use to recognize the pathogen type are called Toll-like receptors (TLR) [Aderem & 
Ulevitch 2000; Schnare et al. 2001;  Raetz et al. 2002; Janeway & Medzhitov 2002; Akira et al. 2006; Campbell et al. 
2015]. TLRs are responsible for macrophage activation [Ozinsky et al. 2000] and proinflammatory 
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cytokine synthesis [Akira et al. 2006]. TLRs are type I integral membrane glycoproteins with 
extracellular domains containing leucine-rich-repeat (LRR) motifs. TLR also have a cytoplasmic 
signaling domain homologous to the domain of interleukin 1 receptor (IL-1R), another membrane-
bound receptor, with which by the way TLRs share a common pathway. This domain is called 
Toll/IL-1R homology (TIR) domain. Different TLRs recognize different PAMP regions, be it peptides, 
polysaccharides, lipids, nucleic acids, ribonucleic acids or some other molecules. For gram-positive 
bacteria those PAMP regions would be a lipoteicoic acid (LTA), a lipoprotein and a peptidocan (PG). 
For gram-negative bacteria it would be a lipopolysaccharide (LPS), or more precisely the “lipid A” 
component of this LPS molecule. Both LTA, PG, lipoproteins and LPS are integrated parts of the 
bacterial cell wall [Schnare et al. 2001; Janeway & Medzhitov 2002; Akira et al. 2006; Campbell et al. 2015].
   Figure 2.1.1 shows, where the aforementioned PAMP molecules are found in bacteria.
Figure 2.1.1. Cell wall components of gram-positive and gram-negative
bacterias respectively: lipoprotein, lipoteichoic acid (LTA),
peptidoglycan (PG) and lipopolysaccharide (LPS)
[Akira et al. 2006].
Acquired Immunity
   The acquired, also known as specific or adaptive, immunity is a much slower defensive response 
which is activated at a later stage of infection. It could take several day to weeks for the adaptive 
immune response to develop. Nonetheless it is more specific in it's recognition of different 
pathogens when compared to the innate system. The acquired immunity is also characterized by 
the immunological memory and a greater specificity when compared to the innate system [Akira et 
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al. 2006; Parkin & Cohen 2001; Campbell et al. 2015; Gumbleton & Furr 2004].  Lymphocytes are the cells of the
adaptive immune system. They are leukocytes like neutrophils and eosinophils. Lymphocytes are 
divided in to two cell types: B lymphocytes and T lymphocytes (or simply B cells and T cells). Those 
T cells are further divided in to two subgroups: helper T (CD4 or CD4+) cells and cytotoxic T (CD8 or
CD8+) cells [Parkin & Cohen 2001; Campbell et al. 2015; Widmaier et al. 2008].
   There are two types of the adaptive immunity: the humoral adaptive immunity and the cell-
mediated adaptive immunity. The humoral immune response occurs in blood and lymph where 
antibodies help to neutralize pathogens. B cells are part of the humoral immunity system  . The 
cell-mediated immune response is characterized by cytotoxic T cells addressing infection in the 
cells of the host. Helper T cells can be looked upon as mediators, which involve both B 
lymphocytes and cytotoxic T lymphocytes [Campbell et al. 2015; Gumbleton & Furr 2004].
Acquired Immunity, Pathogen Recognition
   The acquired immunity recognizes the pathogen through epitopes. Epitopes are the molecular 
patterns on the pathogen conceptually similar to PAMPs recognized by the innate immunity [Delves 
& Roitt 2000; Gumbleton & Furr 2004]. Epitopes are recognized by the antigen receptors. Those receptors
are either T cell receptors (TCR) or B cell antibodies [Gumbleton & Furr 2004]. The antibodies of the B 
cell are immunoglobulins (Ig). There are five types of immunoglobulines known: immunoglobulins 
A (IgA), immunoglobulins D (IgD), immunoglobulins E (IgE), immunoglobulins G (IgG) and 
immunoglobulins M (IgM) [Edelman 1973; Gumbleton & Furr 2004]. Immunoglobulins are symetrical Y-
shaped polypeptides and consist of four subunits:  two light chains and two heavy chains. They 
have hypervariable regions, which are the ones responsible for high affinity to different epitopes 
through amino acid variation [Gumbleton & Furr 2004].
Acquired Immunity, Modus Operandi
   During the first internal exposure to the pathogen this it's epitope is presented to the helper T 
lymphocytes. This happens through an antigen-presenting cell, either a DC, a macrophage  or a B 
lymphocyte, which is in direct contact with the pathogen. Helper T lymphocytes both create 
memory helper T cells and activate both B lymphocytes and cytotoxic T lymphocytes. B cells 
produce both memory T cells and plasma cells. Plasma cells secret their antibodies. Those released
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Immunoglobulins recognize and attach to the epitopes of the antigen once presented to the helper
T cell. This process is called neutralization. When neutralized by Igs the pathogen is phagocytized. 
This Ig mediated phagocytosis is called an opsonization. In the meantime the activated cytotoxic T 
cells also have two functions. The first is to attack the presented infection and the second is to 
produce memory cytotoxic T cells. Both memory B cells, memory helper T cells and memory 
cytotoxic T cells are kept by the host as it's immunological memory of the presented antigen. This 
makes the host to “remember” and respond more adequately to this very same infection should it 
occur next time. The immunological response during the first time of infection is known as a 
primary immune response. This time of response peaks about 10 - 17 days after the exposure. The 
immunological response mediated by the immunologic memory during the recurring infection of 
the same type is called a secondary response. It peaks already after 2 - 7 days after the exposure 
[Campbell et al. 2015].   A figure 2.1.2 summarizes the human adaptive immune system.
Figure 2.1.2. Human adaptive immunity system
[Campbell et al. 2015]
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Innate Immunity, Brief Summarization
   Table X shows a general summarization of the human immunity discussed in this chapter.
Human Immune Response
Innate Response Acquired Response
Barrier Response Internal Response Humoral respons Cell-mediated
response
commensal bacteria
+
lysozyme
eosinophiles
+
neutrophiles (pg)
+
macrophages (pg)
+
DC (pg)
+
NK
B cells
+
memory B cells
+
plasma cells
+
Ig
helper T cells
+
memory helperT cells
cytotoxic T cells
+
memory cytotoxic T
cells
Table 2.1.1. Human Immunity and it's elements.
Note: types of immune response are shown in bold with their elements below them. Elements shown in italic are
leukocytes. “Pg” in parentheses denotes, that the element is a phagocyte. (Helper T cells and memory helper T cells
operate in both humoral and mediated systems.)
2.2 BRIEF OVERVIEW OF VIRULENCE FACTORS OF STAPHYLOCOCCUS AUREUS
   As it will be shown below the virulence factors could be divided in to two groups. The first ones 
are targeting the host body itself. The second ones are targeting the immune system of the host. 
The last group is therefore of special interest when talking about immunization against S. aureus.
   Some of the virulence factors associated with S. aureus are Protein A, Panton-Valentin Leukocidin
(PVL), γ-hemolysin, phenol-soluble modulin α (PSMα), arginine-catabolic mobile element (ACME) 
and α-toxin [Lina et al. 1999; David & Daum 2010; Otto 2013; Guimaraes et al. 2014].
Synergohymenotropic Toxins
   Panton-Valentine Leukocidin (PVL) and γ-hemolysin belong to the family of the 
synergohymenotropic toxins. These toxines damage membranes of the host defence cells and 
erythrocytes by a cooperative action  of two classes of proteins – F and S [Supersac et al. 1993].
   PVL vas first described by Van de Velde in 1894 and then by Panton and Valentine in early 1930. 
PVL an extracellular product of S. aureus and is encoded by two genes, LukF-PV and LukS-PV 
respectively  [David & Daum 2010; Gillet et al. 2002; Spaan et al. 2013a]. PVL and γ-hemolysin are also β-
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barrel pore-forming toxins (β-PFT) primarily in the case of neutrophils and macrophages. PVL is 
also cytotoxic for monocytes as well but to a lesser degree. During infection LukS-PV binds to 
human receptors C5aR and C5L2. In case with neutrophils C5aR acts as a major receptor of the two
when speaking of targeting by LukS-PV of PVL. When LukS-PV is bound to the target cell, it triggers 
binding of LukF-PV subunit. This induces the assembly of lytic poreforming octamers. The general 
mechanism of action of pore-forming is twofold: one subunit interact with a phospholipid bilayer 
while the other interacts with the cytosol and it's contents. This action ultimately leads to cell 
death [Gillet et al. 2002; Spaan et al. 2013a; Thammavongsa et al. 2015]. Before the outbreak of Community-
associated Methicillin-resistant S. aureus (CA-MRSA) in mid nienties PVL was believed to be present
in less than 5 % of S. aureus isolates, although PVL genes were found twice in the Japanese ST30 
strain, first in 1979 and then in 1985. PVL was primarily associated with necrotizing pneumonia, 
skin infections such like furunculosis, necrotic skin infections and cutaneous abscesses  [Lina et al. 
1999; Gillet et al. 2002; Labandeira-Rey et al. 2007; David & Daum 2010].
    γ-hemolysin is produced by more than 99 percent of S. aureus strains. It's class S consists of two 
parts: HlgA and HlgC. The F class consists of HlgB. This produces two S/F dimers: HlgA/HlgB and 
HlgA/HlgC. Those aforementioned γ-hemolysin dimers have leukotoxic properties. The are able to 
lyse human erythrocytes.  γ-hemolysin subunits also create dimers with PVL subunits resulting in 
following dimers: HlgA/HlgB, HlgA/HlgC,  LukS-PV/LukF-PV, LukS-PV/HglB, HlgA/LukF-PV and 
HlgC/LukF-PV [Lina et al. 1999]. 
Arginine-catabolic Mobile Element
   Arginine-catabolic mobile Element (ACME) is a30.9 kb long DNA element found in CA-MRSA. It 
contains 33 expressed reading frames. It is often present in USA300 , most predominant variation 
of CA-MRSA after year 2000. It is believed that ACME enhances CA-MRSA strains to colonize the 
skin of healthy individuals [David & Daum 2010].
Phenol-soluble Modulins
   Phenol-soluble Modulin α (PSMα) has a strong cytolytic function towards neutrophiles and 
erythrocytes [Cheung et al. 2012; Otto 2013; Surewaard et al. 2013]. Besides being able to lyse neutrophiles
and erythrocytes PSMs can also lyse peripheral blood mononuclear cells as well. Nonethe less only 
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PSMα has this cytolytic activity but PSMβ does not for example. It is not yet understood, why it is 
so [Surewaard et al. 2013].  Besides that PSMs are also responsible for biofilm formation by forming 
fibril-like structures as well as for the biofilm detachment, which causes a better spread of the 
biofilm-associated infection. PSMs are also generally known for triggering the inflammatory 
response through their interaction with the formyl peptide receptor 2 (FPR2) of the host. 
Neutrophils get activated through this receptor after what a chemotactic attraction takes place.  
Neutrophiles engulfes S. aureus together with PSM through phagocytosis. After phagocytosis the 
microbicidal granule components and reactive oxygen species are released inside the neutrophiles 
in order to destroy S. aureus. Nonetheless the PSMα peptides of S. aureus kill the neutrophiles 
from inside by lysis after this phagocytotic engulfment had taken place. This intracellular activity of
the PSMα is further supported by the fact, that PSM is inhibited by serum lipoproteins  [Otto 2013; 
Surewaard et al. 2013]. PSMα is a small aphipathic α-peptide consisting of 20-25 amino acids [Otto 
2013].
 PSMα peptides of S. aureus are known as  PSMα1,  PSMα2,  PSMα3 and PSMα4 and are encoded 
in the psma operon of the bacteria. δ-toxin is also  PSMα and is cytolytic as well [Otto 2013; 
Surewaard et al. 2013].
α-toxin
   α-toxin (AT) is a β-PFT, just like PVL and γ-hemolysin. AT binds to A-disintegrin and 
metalloprotease 10 (ADAM10) in order to agglomerate and create a pore in the membrane of the 
target cell [Bhakdi & Tranum-Jensen 1991; Foster 2005; Berube & Wardenburg. 2013; Tkaczyk et al. 2013; 
Thammavongsa et al. 2015]. It also activates ADAM10 mediated proteolysis of E-cadherin present in 
cell-cell adhesive contacts. This might contribute to a better dissemination of S. aureus [Tkaczyk et al.
2013]. AT has been shown to intoxicate epithelial cells, endothelial cells, T cells, monocytes, 
pneumocytes, keratinocytes, macrophages and neutrophiles [Berube & Wardenburg. 2013; 
Thammavongsa et al. 2015]. Although it is believed that AT is a lesser contributor to the bacterial 
cytolysis of neutrophils and erythrocytes [Chen et al. 2015]. The secondary function of AT is host 
immune response manipulation. It is a known immunogen. It induces the release of cytokines like 
interleukin 1β (IL-1β) and vasoactive agents [Bhakdi & Tranum-Jensen 1991; Berube & Wardenburg. 2013; 
Otto 2013]. AT is encoded I hla locus of the bacterial DNA. The peptide consists of 319 amino acids. 
The outer diameter of it's  β-barrel ring structure is 10 nm and the inner one is approximately 2 – 3
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nm [Berube & Wardenburg. 2013].
Protein A
   Protein A (spA) is a curface molecule of S. aureus [Falugi et al. 2013] binds to both the Fc region of 
immunoglobulin G (IgG) and the Fab region of the B-cell receptor thus blocking the subsequent 
obsonophagocytosis. This leads to a B-cell death in vitro [David & Daum 2010; Falugi et al. 2013; 
Kobayashi et al. 2013].
Protein A is also responsible for the initiation of the proinflammatory mechanism through it's 
activation of a tumor necrosis factor receptor 1 (TNFR1). It was also shown to enhance the activity 
of  α-toxin in a murine model of skin infection [Fournier & Philpott 2005; David & Daum 2010].
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3. INNATE IMMUNITY AS THERAPY AGAINST STAPHYLOCOCCUS AUREUS
3.1 INNATE IMMUNITY AS THERAPY AGAINST STAPHYLOCOCCUS AUREUS
   One of the promising therapeutic approaches in combating S. aureus could be the boosting of 
the innate immune system with an immunogen component just like an adjuvant, a substance non-
specifically enhancing the antigen specific immunity [Delves & Roitt 2000; Kaisho & Akira 2002; Romagne 
2007; Miller & Cho 2011]. In order to do that one must first at foremost find the entry pints to the 
innate immunity system as well as understand the pathway and metabolic products those entry 
points might bring. This is one of the scope of part 3.1 in chapter 3. The scope of part 3.2 is to find 
out whether this innate immunity therapeutic approach is ineffective against the ever adaptable S.
aureus.
Extracellular Innate Immunity Activation by Gram-positive Bacteria
   It was described in chapter 2 the membrane-bound Toll-like receptors (TLR) are central in 
recognizing pathogen in the innate immune system [Janeway & Medzhitov 2002; Pietrocola et al. 2011]. 
The host recognizes the bacteria through an aforementioned conserved PAMP region. For the 
gram-positive bacteria, to which S. aureus belongs, those patterns are following molecules: a 
peptidoglycan (PG), a lipoteichoic acid (LTA) and a lipoprotein. The Toll-like receptor associated 
with those PAMP ligands is TLR2. Depending on the PAMP molecule region TLR2 might not be able 
to be activated when alone, even though TLR2 is involved in recognition of this pattern. In that 
case, depending on the PAMP molecule, TLR2 forms a heterodimer by ether coupling with TLR1 or 
TLR6: TLR2/TLR1 or TLR2/TLR6. This heterodimer recognizes the PAMP and initiates a pathway to 
activating of the innate immunity system [Aderem & Ulevitch 2000; Ozinsky et al. 2000; Fournier & Philpott 
2005; Akira et al. 2006].  TLR2 also recognizes PSM virulence factors of S. aureus [Fournier & Philipott, 
2005].
   After activation by ether PG, LTA or lipoprotein the Toll-like receptor undergoes a conformational 
change. TLR cytoplasmic domain is homologous to that of an Interleukin 1 (IL-1) receptor. 
Therefore this homologous domain is known as a Toll/IL-1R (TIR) domain.  TIR-domain-containing 
adaptor molecules connect to this TIR domain of the TLR [Bowie & O'Neill 2000; Yamamoto et al 2002a; 
Aderem 2003; Oshiumi et al 2003]. Those are myeloid-differentiation-factor 88 (MyD88) molecules and 
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TIR-associated protein/MyD88-adaptor-like (TIRAP/MAL) molecules. TIRAP/MAL serves as an 
adapter between MyD88 and TLR [Fitzgerald et al. 2001; Horng et al. 2001; Horng et al. 2002; Yamamoto et al. 
2002b; Akira et al. 2006].
   MyD88 recruits 2 IL-1R-associated kinases (IRAK): IRAK-1 and IRAK4. After IRAK-1 associates with 
My88 it's phosphorylated by the activated IRAK4.  Autophosphorylated IRAK then forms a complex 
with tumor-necrosis-factor-receptor-associated-factor 6 (TRAF6). This oligomerizates TRAF6, which 
in turn activates TAK-1 (MAP 3-kinase). This activates IkB kinases, which then phosphorylate IkB. 
This leads to transport of nuclear factor-kB (NF-kB) to the nucleus. Activator protein-1 (AP-1) is also
activated (both AP-1 and NF-kB are transcription factors for cytokine production) [Aderem & Ulevitch 
2000; Akira et al. 2001; Akira et al. 2003; Beutler & Rietschel 2003; Deng et al. 2000; Wang et al. 2001; Gohda et al. 
2004; Flannery & Bowie 2010]. This cascade results in activating NF-kB, resulting in induction of genes 
involved in proinflammatory cytokine production [Aderem & Ulevitch 2000; Yamamoto et al. 2004; Akira et 
al. 2006].
   There is another transcription factor, IRF-5, which is activated by MyD88 together with TRAF6. 
IRF-5 also activates produktion of proinflammatory cytokins, primarily interleukin 6 (IL-6), 
interleukin 12 (IL-12) and tumour-necrosis factor α[Takaoka et al. 2005].
   To summarize it all up the the extracellular innate innate response on gram-positive bacterial 
infection would be a so-called MyD88-dependent pathway through an activation of the 
membrane-bound TLR2 receptor. The pathway results in induction of 3 transcription factors in 
order to produce cytokines: NF-kB, AP-1 and IRF-5.
Extracellular Innate Immunity Activation, Toll-like Receptor Family
The most interesting thing is though is that there are several other entry point receptors for the 
same MyD88-dependent pathway for producing of the same cytokins as in case with gram-positive
bacteria. Those membrane-bound proteins allow the immunogen to be gram-negative, viral, fungal
and other PAMP elements in order to get the same desired response against the gram-positive 
bacteria.
   Those receptors are actually TLRs as well, and 8 of the 12 discovered TLRs belong to the MyD88-
dependent pathway. Those are TLR1, TLR2, TLR4, TLR5, TLR6, TLR7, TLR9 and TLR11 [Akira et al. 2003;
Akira et al. 2006; Kumar et al. 2009]. Different receptors have different PAMP regions of different 
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microorganisms as it will be discussed. Figure 3.1.1 shows the overview of the MyD88-dependent 
pathway TLR family.
Figure 3.1.1. MyD88-dependent pathway TLRs with some of their PAMP ligands.
“IRAK” on the picture depicts IRAK1/4. TLR11 is not depicted.
(TLR3 is exchanged with TLR11 in the original picture)
[Yamamoto et al. 2004].
   As can be seen on the picture, and as described before, TLR often (but not always) creates a 
heterodimer with either TLR1 or TLR6, depending on the PAMP type[Akira et al. 2006]. Al the other 
known MyD88-dependent TLRs act as monomers when recognizing their specific PAMPs. TLR4 is 
somewhere in-between though. Although it doesn't form a heterodimer, it still requires some 
adaptor molecules in order for it to recognize it's PAMP – the lipopolysaccharide (LPS) molecule of 
the gram-negative cell wall.  LPS binds to the serum protein LPS-binding protein (LBP). This 
complex then interacts with CD14 on macrophages or neutrophils. MD-2 is another adapter 
molecule which is connected to the extracellular part of TLR4. It is required for a successful signal 
transport through this receptor [Hambleton et al. 1996; Shimazu et al. 1999; Aderem & Ulevitch 2000; Beutler &
Rietschel 2003].The TLR4 receptor complex is depicted in figure 3.1.2.
18
Figure 3.1.2. LPS-specific detection by TLR4 through binding with LBP and CD14 
[Aderem & Ulevitch 2000]
   Besides the extracellular adapter molecules TLR4 requires the cytoplasmic TIRAP/MAL adapter in 
order to continue down the MyD88 way, just like TLR2. All the other MyD88 do not need it – the 
connect to MyD88 directly [Horng et al. 2001; Horng et al. 2002; Yamamoto et al. 2002a; Yamamoto et al. 
2002b; Akira et al. 2006]. The figure 3.1.3 shows this.
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Figure 3.1.3. Signalling pathway from TLR activation to expression of the immune
response genes (innate immune response mechanism activa2tion) in humans.
“TIRAP” on the picture depicts TIRAP/MAL.
(Adaptor molecule for TLR5, TLR7 and TLR9 are excluded from the
original picture because of the irrelevance to the topic. MyD88-independent
pathway is excluded for the same reason. TLR11 is added to the original picture)
[Akira et al. 2003; Yamamoto et al., 2004]
   It is worth mentioning, that TLRs are also involved in MyD88 mediated pathways, which are not  
the initial innate immunity recognition pattern due to employment of Immunoglobulins as primary
receptors. The example could be some of TLR7 and TLR immune memory response of the 
plasmacytoid-dendritic cells (pDC). Because this particular MyD88 cascade is a part of an IgG-
induced immune memory response, it is outside the scope of this text [Parcina et al. 2008]
Extracellular Innate Immunity Activation, Interleukin-1 Receptor/Toll-like Receptor Superfamily
Actually, the TLR-family is a part of a the Interleukin-1 receptor/Toll-like receptor superfamily, 
which, as name suggests, also includes IL-1 receptors. This connection is due to the TIR domain (or 
TIR homology domain) already discussed [Bowie & O'Neill 2000]. And, as the matter of fact IL-1 
receptor also leads to the MyD88-dependent pathway – the pathway for innate immunity 
activation for a gram positive bacteria [Weber et al. 2010; Akira et al. 2006]. IL-1 activates the cells (T 
cells) of the adaptive immunity as well [Fournier & Philpott 2005].
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Summarization of Extracellular Receptors and their Ligands
   A summarization of all MyD88 receptors and some their ligands is presented in table 3.1.1.
MyD88 Receptor Ligand/PAMP Microorganism
TLR1/TLR2 lipopeptid
gram-positive bacteriaTLR2 PG, PSM
TLR2/TLR6 LTA, lipopeptid
TLR4 LPS gram-negative bacteria
TLR5 flagellin flagellated bacteria
TLR7 RNA virus
TLR9 DNA bacteria
TLR11 profilin protozoa
Table 3.1.1. Summarization of MyD88 recepters and some of their ligands
[Kaisho & Akira. 2002; Fournier & Philpott 2005; Akira et al. 2006].
   There are much more ligands for many of the receptors, here [Akira et al. 2006]. Table 3.1.1 
presents only the common ligands in order to convey a concept of those PRR receptors.
   The MyD88-dependent pathway with all it's iL-1/TLR receptors with all those different receptor 
target sites and their immunogen ligands  activating innate immunity through an inflammatory 
response might seem like an obvious therapeutic alternative to antibiotics [Kaisho & Akira. 2002; 
Romagne 2007]. Indeed there are already several TLR agonists undergoing clinical trials.  Aldara and 
ANA245 are targeting TLR7. CPG7909, CPG10101, Imoxine and HYB2055 are targeting TLR9. MPL 
and CRX675 target TLR4, while Poly AU targets TLR3. Some of those substances are already 
marketed [Romagne 2007].
Intracellular Bacterial Pathogen Innate Immunity Activation
   Should bacteria get inside the cell there are pathogen detection systems like nucleotide-binding-
oligomerization-domain-leucine-rich-repeat (NOD-LRR) proteins or mammalian nucleotide-
binding-site LRR (NBS-LRR) proteins. NOD-LRR proteins, NOD1 and NOD2, detect γ-D-glutamyl-
meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), found in bacterial PG. When 
those are bound to NOD1 and NOD2 it results in NF-kB activation. NOD1 is also known as a 
caspase-ativating-and-recruitment-domain 4 (CARD4), and NOD2 as CARD15. NOD1 and NOD2 
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have also been reported to induce an apoptosis, although it not known, whether it occurs under 
normal physiological conditions [Girardin et al. 2003; Chamaillard et al. 2003; Athman & Philpott 2004; Fournier 
& Philpott 2005; Akira et al. 2006].
Tumor Necrosis Factor-α Receptor 1
   The TNF-α receptor 1 (TNFR1) is found in airway epithelium. It recognizes one of the virulence 
factors of S. aureus – protein A. This induces IL-8 production as well as  NF-kB activation[Fournier & 
Philpott 2005; David & Daum 2010].
HIF-1 Mediated Innate Immunity Activation
Hypoxia inducible factor-1 (HIF-1) is a transcriptional factor which regulates the oxygen 
homeostasis and adaptation of the cell to low oxygen stress (hypoxia). It is a dimer consisting of 2 
subunits: HIF-1 α and HIF-1 β  [Semenza 2001; Okumura et al. 2012; Rius et al. 2008]. But the level HIF-1 in 
macrophages is also raised by bacterial infection as well [Peyssonnaux et al. 2008]. No matter the 
origin of induction HIF-1 α is discovered to play a crucial role in inducing of bactericidal effect in 
both myeloid phagocytes and keratinocytes and a production of NO which also is believed to have 
an antimicrobial effect against several bacterial species [Peyssonnaux et al. 2005; Peyssonnaux et al. 2008]. 
Level of HIF-1 α is low in both macrophages and neutrophils in aseptic oxygenated (normoxic) 
blood stream [Zinkernagel et al. 2007]. The picture below depicts the overall model of HIF-1 α 
transcriptional regulation of phagocytic innate immune response.
   Already in 2007 was HIF-1 α believed to be the next therapeutic target for infectious diseases 
[Zinkernagel et al. 2007]. Then Akebia Therapeutics developed af a new substance called AKB-4924. In 
2012 the group of researchers (with 2 employees of Akebia Therapeutics among them) published 
an article about their research that should show that AKB-4924 induced levels of  HIF-1 α and thus 
enhanced the bactericidal effect of keratinocytes [Okumura et al. 2012]. In other words it should show
that AKB-4924 could be used as a prophylactic immunization booster. It was shown through an “in 
vitro killing assay” where the cell culture was introduced to AKB-4924 before being infected with S.
aureus. Compared to control it showed a positive result. The mouse infection model where mice 
were treated with AKB-4924 24 hours after the S. aureus infection showed that the treated mice 
healed approximately 70% faster then the control group where the organism failed to prevent 
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spreading of the infection. It was also shown that AKB-4924 didn't have the bactericidal effect 
nonetheless was more effective against both MSSA and especially MRSA when compared to 
vancomycin, daptomycin and penicillin [Okumura et al. 2012]. 
In 2013 there was published another paper, this time an independent work about an assay where 
AKB-4924 showed the same positive result regarding innate immunity boosting and a neutrophilic 
recruitment through the very same HIF-1 α induction [Leire et al. 2013].
3.2 INNATE IMMUNITY EVASION BY STAPHYLOCOCCUS AUREUS
   Unfortunately, as seen in chapter 2, S. aureus developed a range of molecular “tools”, like 
virulence factors, to evade innate immunity. There is a rich plethora of these S. aureus immunity 
evasive substances [Thammavongsa et al. 2015]. This text will only focus on those substances, already 
mentioned in previous chapter as well as those molecules , which specifically attack or manipulate 
the entry sites (MYD88-dependent PRRs, NOD-LRRs, TNFR1 and HIF-1 ) as well as “weapons” of the
innate immunity (phagocytes, eosinophiles and NKs). This way it would be clear whether the found
therapeutic strategy of innate immunity activation with either MyD88-dependent PPRs,
NOD-LRRs, TNFR1 and HIF1 would work against S. aureus infection.
Staphylococcus aureus Evasive Manipulation of Innate Immunity Entry Sites
   In case with MyD88-dependent pathway PRRs it is known, that S. aureus can employ a 
staphylococcal superantigen-like protein 3 (SSL3) to block the TLR1/TLR2 and TLR2/TLR6 
heterodimers. In this case the innate immunity of the host would not be able to recognize the 
PAMP regions of S. aureus like LTA and lipopeptides. SSL3 belongs to am SSL family of proteins, 
which are homologous to staphylococcal superantigenes. Those superantigens crosslink B cell 
receptors and T cell receptors to evade the immunity through a lymphocyte proliferation [Yokoyama 
et al. 2012; Thammavongsa et al. 2015].
Staphylococcus aureus Evasive Manipulation of Phagocytes
   SSL10 blocks C-X-C chemokine receptor 4 (CXCR4) interfering with neutrophilic attraction 
[Thammavongsa et al. 2015].
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   PSM, a virulence factor discussed in chapter 2, is involved in several mechanisms. Those are 
chemotaxis, induction of FRR2 inflammatory response. Biofilm formation and lysis af neutrophiles 
and macrophages, after S. aureus is phagocytized. It can lyse leukocytes in general. Survival of S. in 
ROS environment when phagocytized can be ascribed to several substances. Antioxidants like 
staphyloxanthin, superoxid dismutases (sodA + sodM) and catalase (catG) reduce the oxidative 
stress of ROS reagents. Alkylperoxid reductase protects against phagocytic hydrogen peroxide 
[Fournier & Philpott 2005; Thammavongsa et al. 2015].
Staphylococcal aureolysin (Aur) cleaves antimicrobial peptides) [Thammavongsa et al. 2015].
   LeukocidinAB (LukAB), LeukocidinED (LukED), PVL, γ-hemolysin and  α-toxin (AT) are all β-PFTs 
both pore-forming toxins that can lyse both neutrophiles and macrophages. PVL kills neutrophils 
through interaction with C5aR, as mentioned earlier [Foster 2005; Berube & Wardenburg. 2013; Spaan et al.
2013a; Thammavongsa et al. 2015].
   Chemotaxis inhibitory protein of S. aureus (CHIPs), formyl peptide receptor-like 1 inhibitor (FLIPr) 
and it's hologue FLIPr-like (FLIPrL) are countering neutrophilic attraction. CHIPs, produced by about
60% S. aureus strains, binds to human formyl-peptide receptor 1 (FPR1) and C5aR. FLIPr inhibits 
FPR2, while FLIPrL inhibits both FPR1 and FPR2 [Foster 2005; Spaan et al. 2013a; Spaan et al. 2013b; 
Thammavongsa et al. 2015].
   Although in innate system phagocytes, and especially neutrophiles, are the most important 
players in destroying S. aureus, the bacteria has evolved to kill those very same cells, which killed it
before. Therefore the phagocytosys of S. aureus became more or less a “game of chance”, as it is 
illustrated in Figure 3.2.1 in case with neutrophiles.
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Figure 3.2.1. S. aureus versus Neutrophiles – a “game of chance”
[Rigby & DeLeo 2012].
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DISCUSSION
   It was shown, that an innate immune response can be activated through several biological 
mediators of the host. Those mediators or entry points could be divided in to four groups: MyD88-
dependent membrane-bound PRRs for en extracellular activation, NOD-LRRs for en intracellular 
activation, TNFR1 and HIF-1.
   MyDD88 PRRs like IL-1 receptor, TLR4, TLR5, TLR7, TLR9 and TLR11 all produce the same  
proinflammatory response, as if it was done by a TLR2 (or it's heterodimers TLR1/TLR2 and 
TLR2/TLR6) against S. aureus. That “mimicking” of TLR2 means, that even though S. aureus can 
block TLR2, the situation can still be circumvented, and the patient cured, by choosing one of the 
other receptors. A rich plethora of PAMP ligands is available for many of those nine receptors, 
which makes it easier to find an appropriate immunogen to induce immunity against S. aureus.
   The intracellular activation must imply some kind of lysis in order to for it to be productive in 
terms of innate immunity. It is using an activation of NF-kB, just like in case with MyD88 PRRs.
Although in theory it might be feasible, it might be quite laborious, if not to say unrealistic in 
practice. Low repeatability and risk of sepsis and tissue damage is characterizing this therapeutic 
approach. In theory it could be done in case with a severe skin damage or infection, where other 
therapeutic approaches against S. aureus might be inapplicable.
   Both TNFR1 and HIF1 approaches are rather promising. TNFR1 is especially interesting, because it
can detect the virulence factor PSM. But then the receptor is situated in the airway epithelium. 
Usefulness of TNFR1 approach is defined by the receptor placement in the epithelium. Overall 
though this therapeutic approach seems to be impractical and with low repeatability as well as risk
of implication.
   Immunity induction via either MyD88 PRR pathway or HIF-1 activation would be two reasonable 
therapeutic choices. Due to a variety and a relative low research and manufacturing cost of 
immunogens available for MyD88 PPRs compared to pharmaceutic activators of HIF-1 the MyD88 
looks like a favourite therapeutic strategy, should the innate immunity be used therapeutically 
against S. aureus. Unfortunately the phagocytic cells, like neutrophils and macrophages, which are 
primarily combating S. aureus. are targeted by the virulence factors of S. aureus to such a severe 
degree, that it converts the innate immunity induction therapy (through either MyD88 PRR 
pathway or by activating HIF-1) into a “game of chance” in terms of success. Therefore the focus 
should be shifted towards either a combined immunogen therapy (innate immunity therapy 
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supporting the adaptive immunity therapy) or to a vaccination altogether, should immunity be an 
alternative to antibiotics. Actually, in this text it was , that IL-1 receptor actet like an inducing factor
for adopted immunity through the activation of T cells. In that case the innate system could 
support the acquired immunity through administering of interleukin-1 or interleukin-1 analogs.
OTHER
   In this text the primary focus was to find out which innate immunity induction pathways there 
are for gram-negative bacteria to which Staphylococcus aureus belongs. The could be many 
approaches, therefor it was important to define what to be included and what to be included in 
the topic of activation of the innate immunity system. Although the focus was on Toll-like receptors
, it was also shown the interleukin pathway could be promissing as well. But it might not be the 
wanted immunune response towards the gram-negative bacterial infection. As can be seen from 
the articles used in this area, the field of the innate immune system alone when not talking about 
the whole immunity system by including the adaptive immunity system as well the topic of study 
of the immunity system is enormous. And the research interest is as big if not bgger as ever. 
Therefore in order to shed light on whether it is possible to use innate immunity induction type of 
therapy it is very important to define the boarders or the scope of the study. By doing so one gets 
to the best results in terms of details. The alternative could be, that the topic of discussion might 
be broad but no to deep. The details and results when working with a literature project directly 
depent on whether or not the premises and borders of the project are define from the beginning. 
If it is so, there is a chance of to get a much clearer picture the subject. Therefore the author of this
text tried to define the not only the goal but also the borders of this literature study.
   The goal of the study was to find whether or not an activation of the innate immunity system 
could be studied as a potential area for a future therapeutic approach in treating Staphylococcus 
aureus infection when considering the well known fact of numerous failed attempts to address the 
problem if this highly organism with antibiotics.
   In order to understand whether the innate immunity system could be used to combat 
Staphylococcus aureus autonomously after being activated one must understand the metabolic 
and signaling pathways characteristic for the innate immunity. After that it is important to find the 
access points to those pathways. The need to understanding of whit immunogen metabolites do 
ligate or in other way interact with those entry points. Although those ligands are described to 
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some minor degree it was never the pthe primary objective to focus on them. The first step was to 
localize the entry pionts.
   As it is known the innate immunity system has a very rapid but nonetheless nonspecific and 
almost similar response to a wide variety of pathogens. It might be, that an organism had a few 
low affinity (when comparing to immunoglobulins) receptors. And those receptors could be on the 
epithelial cells, inside tissues or even inside the cells. Which was pretty much what was found in 
respect to MyD88 PRRs, NOD LRRs and TNFR1 (when speaking innate immunity). HIF-1 in that case
would be a separate subject.
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